Just been looking at Pfizer's situation and there's quite a bit to unpack here. The company is dealing with some serious near-term headwinds that most people aren't fully pricing in yet.

So here's the thing - Pfizer is facing what's called an LOE cliff, and LOE stands for Loss of Exclusivity. Basically, when patents expire on major drugs, generic versions flood the market and revenues take a hit. For Pfizer, this LOE event is hitting hard. Several blockbuster drugs are losing patent protection in the 2026-2030 window: Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi are all facing expiration. The company is already warning that this LOE cliff will hurt sales by around $1.5 billion in 2026 alone.

But that's not even the biggest problem. COVID revenues are collapsing. Comirnaty and Paxlovid peaked in 2022 and have been declining ever since. This year they're expecting COVID revenues to drop to around $5 billion, down from $6.7 billion last year. With lower infection rates, that trend is only going to continue.

Then there's the Medicare Part D redesign under the Inflation Reduction Act. Higher-priced drugs like Eliquis, Vyndaqel and Ibrance are getting hit hardest. This unfavorable impact started in 2025 and is expected to persist through 2026 and beyond.

Combining all these pressures - the LOE situation with expiring patents, declining COVID sales, and the Medicare headwinds - Pfizer's 2026 guidance is basically flat to slightly negative for both earnings and revenues. That's not exactly inspiring for investors.

What's interesting is how Pfizer is responding. They're actively rebuilding their pipeline in oncology and obesity, betting these areas will drive growth by 2028 and beyond. They've been doing acquisitions to replace lost COVID revenues and launched a cost realignment program to protect margins. But here's the reality - their new and acquired products haven't yet been able to fully offset the revenue losses from legacy products and the COVID decline.

Looking at the competitive landscape, Pfizer is up against some serious players in oncology. AstraZeneca has oncology representing 44% of revenues with strong growth in drugs like Tagrisso and Enhertu. Merck's Keytruda alone brought in $31.7 billion in sales last year. J&J's oncology sales hit $25.4 billion with momentum from new drugs like Carvykti and Tecvayli. Even Bristol-Myers is holding strong with Opdivo generating $10 billion.

From a valuation angle, Pfizer actually looks reasonable right now. The stock is trading at 9.04x forward earnings, well below the industry average of 18.22x and below its own five-year mean of 10.20x. That suggests the market has already priced in some of these headwinds. The consensus estimate for 2026 earnings came in at $2.97 per share, with 2027 expected at $2.83.

The real question is whether Pfizer can execute on its pipeline transformation before the LOE impact becomes too severe. The company is essentially in a race against time - they need their oncology and obesity programs to gain meaningful traction while managing the patent cliff. It's a challenging situation, but the valuation does offer some margin of safety for investors willing to bet on a turnaround.